SUO held in conjunction with the AUA Annual Meeting
Saturday, May 4, 2013
Manchester Grand Hyatt San Diego
Elizabeth A – D
San Diego, CA

The morning session is a combined meeting of the Society of Urologic Oncology (SUO) and the Society of Basic Urologic Research (SBUR).

SUO/SBUR JOINT MEETING (MORNING PROGRAM)
Location: Elizabeth A – D

 Targets and Therapies
7:55 a.m. – 8:00 a.m.

Introduction and Welcome
Marianne Sadar, PhD
BC Cancer Agency
Edward M. Messing, MD
University of Rochester

I. IMMUNOBASED STRATEGIES FOR TREATMENT OF UROLOGIC MALIGNANCY
Moderator: Edward Messing, MD
8:00 a.m. – 8:20 a.m.
DNA Vaccines as Targeted Therapy for Prostate Cancer
Douglas McNeel, MD, PhD
Wisconsin Institute of Medical Research

8:20 a.m. – 8:25 a.m.
Questions & Discussion

8:25 a.m. – 8:45 a.m.
Investigating Immune Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma
Padmanee Sharma, MD, PhD
MD Anderson Cancer Center

8:45 a.m. – 8:50 a.m.
Questions & Discussion

8:50 a.m. – 9:10 a.m.
Molecular Grenades for Metastatic Prostate Cancer
John T. Isaacs, PhD
Johns Hopkins University School of Medicine

9:10 a.m. – 9:15 a.m.
Questions & Discussion

 II. FROM DISCOVERY OF TARGETS TO DEVELOPING THERAPIES
Moderator: Marianne Sadar, PhD
9:15 a.m. – 9:35 a.m.
Modulating Damage Responses in the Tumor Microenvironment Enhances Cancer Therapeutics
Peter Nelson, MD
University of Washington

9:35 a.m. – 9:40 a.m.
Questions & Discussion

9:40 a.m. – 10:00 a.m.
Targeting EZH2 in Castration-Resistant Prostate Cancer
Myles A. Brown, MD
Harvard Medical School

10:00 a.m. – 10:05 a.m.
Questions & Discussion

10:05 a.m. – 10:20 a.m.
NR4A Nuclear Receptors as Therapeutic Targets
Orla Conneely, PhD
Baylor College of Medicine

10:25 a.m. – 10:30 a.m.
Questions & Discussion

III. THE COFFEY LECTURESHIP
Moderators: Marianne Sadar, PhD
Edward M. Messing, MD
10:30 a.m. – 11:30 a.m.
Understanding and Managing Early Stage Prostate Cancers
Ronald DePinho, MD
MD Anderson Cancer Center

11:30 a.m. – 12:30 p.m.
SUO Business Meeting Luncheon

SUO SCIENTIFIC MEETING (AFTERNOON PROGRAM)
Location: Elizabeth A – D

12:45 p.m. – 12:55 p.m.
Welcome and Introductions

12:55 p.m. – 2:35 p.m.
Imaging in Urologic Malignancies
Moderator: Li-Ming Su, MD

12:55 p.m. – 1:00 p.m.
Introduction

1:00 p.m. – 1:15 p.m.
Renal Cancer I:
Radiologic Evaluation of the Renal Mass
Stuart G. Silverman, MD
Brigham and Women’s Hospital
1:15 p.m. – 1:25 p.m.  
**Considerations for Renal Dysfunction**  
Richard W. Katzberg, MD  
*University of California School of Medicine*

1:25 p.m. – 1:35 p.m.  
**Cumulative Effects / Costs of Radiation in Follow-Up**  
Erick M. Remer, MD, FACR  
*Imaging Institute & Glickman Urological Institute, Cleveland Clinic*

1:35 p.m. – 1:45 p.m.  
**Novel Imaging Modalities for Renal Masses**  
Chaitanya R. Divgi, MD  
*Columbia University Medical Center*

1:45 p.m. – 2:05 p.m.  
**Prostate Cancer I:**  
**Improvements in MRI and MRS**  
Peter Choyke, MD  
*National Cancer Institute*

2:05 p.m. – 2:25 p.m.  
**Bladder Cancer I:**  
**Novel Imaging Modalities**  
Joseph C. Liao, MD  
*Stanford University*

2:25 p.m. – 2:35 p.m.  
**Panel Discussion / Questions**

2:35 p.m. – 2:40 p.m.  
**Whitemore Lecture Introduction**  
Ashish M. Kamat, MD  
*MD Anderson Cancer Center*

2:40 p.m. – 3:10 p.m.  
**Whitmore Lecture: Problems with the Diagnosis of Prostate Cancer**  
Urs E. Studer, MD  
*University of Ben, Inselpital*

3:10 p.m. – 3:40 p.m.  
**Renal Cancer II:**  
**Management of the 4-10 cm Renal Mass**  
Moderator: Brian R. Lane, MD, PhD

3:36 p.m. – 3:40 p.m.  
**Panel Discussion / Questions**

3:40 p.m. – 4:00 p.m.  
**Penile Cancer:**  
**Management of Intermediate and High Risk Penile Cancer**  
Lance Pagliaro, MD  
*The University of Texas*

4:00 p.m. – 4:30 p.m.  
**Bladder Cancer II:**  
**Management of Non Muscle Invasive Micropapillary Variant**  
Moderator: Jodi K. Maranchie, MD

Saturday, May 4, 2013  
**SUO/SBUR Joint Meeting (Morning Program)**  
Manchester Grand Hyatt  
*Location: Elizabeth A – D*  
7:55 a.m. – 12:45 p.m.

**SUO Business Meeting Luncheon (SUO Members Only)**  
Manchester Grand Hyatt  
*Location: Elizabeth E*  
11:30 a.m. – 12:30 p.m.

**SUO Scientific Meeting (Afternoon Program)**  
Manchester Grand Hyatt  
*Location: Elizabeth A – D*  
12:45 p.m. – 5:20 p.m.

**SUO Reception and Dinner**  
Registration Required  
*Location: San Diego Wine & Culinary Center*  
Attire: Business Attire  
6:30 p.m. – 10:00 p.m.
SUO/SBUR JOINT MEETING EDUCATIONAL NEEDS
(MORNING PROGRAM)

These sessions will specifically address educational needs concerning: 1) immunobased therapies; and 2) identification of resistance mechanisms and potential drug targets.

The first session focuses on immunobased therapies for urologic malignancy. Cancers have adapted mechanisms to escape recognition by the host immune system. Recent advances in our understanding of this process have opened the door to novel therapeutic strategies. These sessions will introduce immune checkpoint inhibition as well as progress in the development of anti-cancer vaccines. It will further explore novel mechanisms for targeted drug delivery.

The second session addresses mechanisms of resistance and strategies for drug development. Many anticancer treatments ultimately fail through acquired resistance. Identification of molecules and mechanisms involved in resistance of malignancies is the first step needed in order to begin to develop novel or improved therapies. A strategy of how to progress forward to the development of small molecule inhibitors or therapeutic biologics once a molecular target is identified remains a major challenge. This session will focus on the targets and mechanisms of resistance to current therapies with newly proposed approaches of drug development being introduced.

SUO/SBUR EDUCATIONAL OBJECTIVES
(MORNING PROGRAM)

At the conclusion of the session, participants should be able to:
1. Explore novel mechanisms for targeted release of toxic molecules within the tumor.
2. Improve familiarity with mechanisms by which tumors escape the natural immune response and novel agents targeting these mechanisms.
3. Understand obstacles to cancer-specific vaccine development and current efforts to overcome them.
4. Learn about the role of the tumor microenvironment and mechanisms of resistance to current therapies for prostate cancer.
5. Become familiar with research approaches for discovering novel therapies.
6. Produce a platform for urologists, medical oncologists, and basic urological scientists to discuss critical gaps in the current understanding of the scientific basis of resistance to current treatments in urologic oncology.

SUO ANNUAL MEETING AT THE AUA EDUCATIONAL NEEDS
(AFTERNOON PROGRAM)

• Deficit in knowledge about cumulative risks of routine radiologic imaging.
• Deficit in performance regarding appropriate use of nuclear imaging studies for cancer surveillance.
• Deficit in competence regarding treatment of RCC such that renal preservation remains underutilized.
• Deficit in knowledge of optimal management of micropapillary urothelial carcinoma.
• Deficit in knowledge of risks and benefits of intermittent vs. continuous androgen blockade, particularly in light of recent clinical trials.

SUO ANNUAL MEETING AT THE AUA EDUCATIONAL OBJECTIVES
(AFTERNOON PROGRAM)

After attending this meeting, attendees should be able to:
a. Recognize the risk of cumulative radiation exposure.
b. Recommend appropriate utilization of novel imaging modalities for GU cancer.
c. Recognize the risks of medical vs surgically-induced renal insufficiency.
d. Recognize micropapillary variant urothelial carcinoma and discuss its unique biology and expected response to surgery, chemotherapy or intravesical therapy.
e. Identify the benefits of androgen blockade and recognize the arguments favoring intermittent vs. continuous androgen blockade for prostate carcinoma.
MARK YOUR CALENDAR

14th Annual SUO Winter Meeting
to discuss current topics and strategies in Urologic Oncology
Wednesday, December 4 – Friday, December 6, 2013

Y.U.O. Dinner: Wednesday, December 4th
SUO Annual Banquet: Thursday, December 5th

Bethesda North Marriott Hotel & Conference Center
5701 Marinelli Road
Bethesda, MD 20852
Phone: (301) 822-9200
Fax: (301) 822-9201

SUO is happy to provide discounted room rates of $199.00, plus applicable tax at the host hotel. The block may sell out prior to the hotel deadline of November 6, 2013; therefore attendees are strongly encouraged to make early reservations.

Visit our website at www.suonet.org for updates on the program agenda and meeting registration.

CALL FOR ABSTRACTS: June 7, 2013
ABSTRACTS DEADLINE: September 6, 2013
THANK YOU TO THE SUO 2012 – 2013 PROMOTIONAL PARTNERS

PLATINUM LEVEL

janssen
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

GOLD LEVEL

Dendreon
Targeting Cancer, Transforming Lives®

SILVER LEVEL

astellas MEDIVATION